PremiumRatingsAlcon’s Long-Term Growth Potential Outweighs Short-Term Challenges: Buy Rating Maintained Closing Bell Movers: Exelixis up 6% on earnings beat Alcon Reports Q1 2025 Results and Launches New Ophthalmic Products PremiumThe FlyAlcon price target raised to $112 from $108 at KeyBanc Alcon price target raised to $110 from $107 at Needham Alcon’s Promising Growth Outlook: Buy Rating Backed by Innovation and Strategic Expansion PremiumThe FlyAlcon upgraded to Buy from Neutral at BofA Alcon downgraded to Hold from Buy at HSBC Alcon announces CE Mark approval for Vivity 
